State of Tennessee Treasury Department held its position in Impax Laboratories, Inc. (NASDAQ:IPXL) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 68,970 shares of the specialty pharmaceutical company’s stock at the close of the second quarter. State of Tennessee Treasury Department owned approximately 0.10% of Impax Laboratories worth $1,110,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Arizona State Retirement System raised its position in Impax Laboratories by 0.3% during the 2nd quarter. Arizona State Retirement System now owns 38,476 shares of the specialty pharmaceutical company’s stock worth $619,000 after buying an additional 100 shares during the last quarter. Massachusetts Financial Services Co. MA raised its position in Impax Laboratories by 1.2% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 14,414 shares of the specialty pharmaceutical company’s stock worth $182,000 after buying an additional 171 shares during the last quarter. Municipal Employees Retirement System of Michigan raised its position in Impax Laboratories by 1.7% during the 1st quarter. Municipal Employees Retirement System of Michigan now owns 16,880 shares of the specialty pharmaceutical company’s stock worth $214,000 after buying an additional 280 shares during the last quarter. Texas Permanent School Fund raised its position in Impax Laboratories by 0.8% during the 2nd quarter. Texas Permanent School Fund now owns 53,810 shares of the specialty pharmaceutical company’s stock worth $866,000 after buying an additional 415 shares during the last quarter. Finally, Bank of Montreal Can raised its position in Impax Laboratories by 0.9% during the 2nd quarter. Bank of Montreal Can now owns 54,383 shares of the specialty pharmaceutical company’s stock worth $875,000 after buying an additional 509 shares during the last quarter. 86.26% of the stock is owned by institutional investors.

A number of equities analysts have issued reports on the stock. BTIG Research reissued a “buy” rating and set a $27.00 price target (up from $20.00) on shares of Impax Laboratories in a research report on Saturday. Deutsche Bank AG reissued a “buy” rating and set a $23.00 price target on shares of Impax Laboratories in a research report on Tuesday, September 19th. Citigroup Inc. raised their price target on shares of Impax Laboratories to $23.00 and gave the stock a “buy” rating in a research report on Tuesday, September 19th. Piper Jaffray Companies reissued a “hold” rating and set a $17.00 price target on shares of Impax Laboratories in a research report on Sunday, September 17th. Finally, Cantor Fitzgerald raised their price target on shares of Impax Laboratories from $20.00 to $25.00 and gave the stock an “overweight” rating in a research report on Monday, September 11th. Four analysts have rated the stock with a sell rating, eleven have issued a hold rating and five have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $19.03.

Impax Laboratories, Inc. (NASDAQ:IPXL) opened at 23.00 on Monday. The stock’s market capitalization is $1.65 billion. Impax Laboratories, Inc. has a 12-month low of $7.75 and a 12-month high of $27.29. The stock’s 50 day moving average is $19.12 and its 200 day moving average is $15.63.

Impax Laboratories (NASDAQ:IPXL) last released its quarterly earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported $0.18 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.14 by $0.04. Impax Laboratories had a positive return on equity of 9.05% and a negative net margin of 71.08%. The business had revenue of $202.08 million during the quarter, compared to analysts’ expectations of $195.62 million. During the same quarter in the prior year, the business earned $0.21 earnings per share. The company’s quarterly revenue was up 17.1% compared to the same quarter last year. Equities research analysts forecast that Impax Laboratories, Inc. will post $0.70 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This article was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another domain, it was copied illegally and republished in violation of international trademark & copyright legislation. The original version of this article can be accessed at https://www.thecerbatgem.com/2017/09/25/state-of-tennessee-treasury-department-continues-to-hold-stake-in-impax-laboratories-inc-ipxl.html.

About Impax Laboratories

Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.

Want to see what other hedge funds are holding IPXL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Impax Laboratories, Inc. (NASDAQ:IPXL).

Institutional Ownership by Quarter for Impax Laboratories (NASDAQ:IPXL)

Receive News & Stock Ratings for Impax Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories Inc. and related stocks with our FREE daily email newsletter.